Morgan Stanley raised its price target for Royalty Pharma, noting regulatory uncertainty and the impact of tariffs.

The entities involved

• Royalty Pharma →

  biopharmaceutical company based in New York City

  • Visteon filed transaction details with the SEC and traded on the Nasdaq stock exchange on June 6, 2026.Sun 17:49
  • Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.Sun 02:34
• Morgan Stanley →

  U.S. investment bank

  • Financial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Mon 17:33
  • Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24
• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

• Morgan Stanley raised its price target and maintained an overweight rating for Wingstop.Jun 8
• CMS proposes broadening criteria for price control, while CBO warns that such controls could discourage investment in the sector.Aug 17
• PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.Sep 5
• Morgan Stanley analyst provides Overweight rating for SpaceX.Sep 5
• Morgan Stanley analysts hiked price targets for Salesforce.Aug 27